ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy.

Details

Language :

English

ISSN :

0732183X

Volume :

42

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

175074445

Full Text :

https://doi.org/10.1200/JCO.2024.42.4_suppl.TPS356